1.0504
2.34%
-0.0196
전일 마감가:
$1.07
열려 있는:
$1.05
하루 거래량:
444.30K
Relative Volume:
0.91
시가총액:
$36.53M
수익:
$3.25M
순이익/손실:
$-116.80M
주가수익비율:
-0.3905
EPS:
-2.69
순현금흐름:
$-98.17M
1주 성능:
-18.36%
1개월 성능:
-36.47%
6개월 성능:
-77.23%
1년 성능:
-92.32%
Rapt Therapeutics Inc Stock (RAPT) Company Profile
명칭
Rapt Therapeutics Inc
전화
(650) 489-9000
주소
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
RAPT을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
RAPT | 1.05 | 36.53M | 3.25M | -116.80M | -98.17M | -2.69 |
VRTX | 449.39 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 747.14 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 595.48 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 246.50 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 108.12 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-05-14 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
2024-05-10 | 다운그레이드 | Barclays | Overweight → Equal Weight |
2024-05-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
2024-02-22 | 다운그레이드 | UBS | Buy → Neutral |
2024-02-21 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2024-02-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2024-02-21 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
2024-02-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
2024-02-16 | 개시 | Evercore ISI | Outperform |
2024-02-15 | 개시 | Wolfe Research | Outperform |
2023-09-14 | 개시 | Berenberg | Buy |
2023-08-09 | 개시 | Stifel | Buy |
2023-06-15 | 개시 | Barclays | Overweight |
2023-01-04 | 개시 | Guggenheim | Buy |
2022-12-01 | 개시 | Goldman | Buy |
2022-09-21 | 개시 | CapitalOne | Overweight |
2022-05-24 | 재개 | Cantor Fitzgerald | Overweight |
2021-12-09 | 개시 | JP Morgan | Overweight |
2021-08-12 | 개시 | SVB Leerink | Outperform |
2021-06-21 | 개시 | Piper Sandler | Overweight |
2020-06-01 | 개시 | H.C. Wainwright | Buy |
2020-05-19 | 개시 | Cantor Fitzgerald | Overweight |
2020-04-13 | 개시 | ROTH Capital | Buy |
2019-11-25 | 개시 | BMO Capital Markets | Outperform |
2019-11-25 | 개시 | UBS | Buy |
2019-11-25 | 개시 | Wells Fargo | Outperform |
모두보기
Rapt Therapeutics Inc 주식(RAPT)의 최신 뉴스
RAPT scraps zelnecirnon program, stock plunges 46% (update) - MSN
RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull - MSN
RAPT Therapeutics stock plunges to 52-week low of $1.11 By Investing.com - Investing.com UK
RAPT Therapeutics announces option repricing to retain talent By Investing.com - Investing.com Nigeria
Leerink Partnrs Issues Optimistic Forecast for RAPT Earnings - MarketBeat
Leerink Partnrs Expects Lower Earnings for RAPT Therapeutics - MarketBeat
RAPT Therapeutics' SWOT analysis: biotech firm faces challenges, seeks new path - Investing.com Canada
RAPT Therapeutics Reports Improved Q3 2024 Results - TipRanks
RAPT Therapeutics' (RAPT) Hold Rating Reaffirmed at Stifel Nicolaus - MarketBeat
Wells Fargo & Company Has Lowered Expectations for RAPT Therapeutics (NASDAQ:RAPT) Stock Price - MarketBeat
RAPT Therapeutics (NASDAQ:RAPT) Earns "Neutral" Rating from HC Wainwright - MarketBeat
RAPT Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewswire
RAPT Therapeutics Narrows Q3 Loss by 41%, Cuts R&D Spend Amid Restructuring | RAPT Stock News - StockTitan
RAPT Therapeutics stock hits 52-week low at $1.49 By Investing.com - Investing.com Australia
RAPT Therapeutics Inc (RAPT) Quarterly 10-Q Report - Quartz
RAPT Therapeutics stock hits 52-week low at $1.49 - Investing.com
Rapt Scraps Zelnecirnon, But Not Giving Up On CCR4 - Citeline News & Insights
Crude Oil Down 3%; Aramark Posts Upbeat Earnings - Benzinga
Nasdaq Moves Lower; Canaan Shares Surge - Benzinga
JPMorgan cuts Rapt Therapeutics to Underweight By Investing.com - Investing.com UK
JPMorgan Chase & Co. Downgrades RAPT Therapeutics (NASDAQ:RAPT) to Underweight - MarketBeat
U.S. Stock market: Binah Capital Group(+105.01%) and CERo Therapeutics(+152.00%) see strong gains, RAPT Therapeutics(−44.12%) declines during mid day trading - Business Upturn
Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury - Benzinga
U.S. Stock market: RAPT Therapeutics drops 41% while CERo Therapeutics surges 136% in early trading - Business Upturn
Dow Jumps Over 400 Points; Monday.com Shares Fall After Q3 Results - Benzinga
Rapt Therapeutics Stops Development of Asthma, Atopic Dermatitis Drug Candidate After Reaction Sidelines Trials - MarketWatch
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury - The Manila Times
Based on Recent FDA Feedback RAPT Therapeutics Stops - GlobeNewswire
RAPT Therapeutics Halts Key Drug Program After FDA Safety Concerns, Liver Injury | RAPT Stock News - StockTitan
Contrasting RAPT Therapeutics (NASDAQ:RAPT) and Elanco Animal Health (NYSE:ELAN) - Defense World
Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth? - Simply Wall St
Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky - Yahoo Finance
Vanguard Group Inc's Strategic Acquisition in RAPT Therapeutics Inc - GuruFocus.com
Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings? - MSN
RAPT Therapeutics stock plunges to 52-week low of $1.65 By Investing.com - Investing.com Australia
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of "Hold" by Analysts - MarketBeat
RAPT Therapeutics stock plunges to 52-week low of $1.65 - Investing.com
RAPT stock touches 52-week low at $1.72 amid sharp yearly decline - Investing.com
Point72 Asset Management L.P. Acquires 706,900 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat
RAPT Therapeutics Inc (RAPT) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Cubist Systematic Strategies LLC Increases Stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat
XTX Topco Ltd Invests $108,000 in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
RAPT Therapeutics' SWOT analysis: biotech stock faces clinical hurdles - Investing.com
RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now - Yahoo Finance
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability - Insider Monkey
15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers - Insider Monkey
RAPT stock touches 52-week low at $1.76 amid sharp annual decline - Investing.com India
Daily Progress: RAPT Therapeutics Inc (RAPT) Drop -7.25, Closing at 1.79 - The Dwinnex
Federated Hermes Inc. Boosts Stock Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat
Acadian Asset Management LLC Raises Stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat
Rapt Therapeutics Inc (RAPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):